Mankind Pharma Ltd. (IN:MANKIND)

:MANKIND

MANKIND

Mankind Pharma Ltd.

RESEARCH TOOLSreports

Want to see IN:MANKIND full AI Analyst Report?

Mankind Pharma Ltd. (MANKIND) Price & Analysis

14 Followers

MANKIND Stock Chart & Stats

₹2202.55

-₹40.15(-1.38%)

At close: Jan 08 4:00 PM EST

₹2202.55

-₹40.15(-1.38%)

Day’s Range― - ―

52-Week Range₹1,909.90 - ₹2,726.75

Previous CloseN/A

Volume302.66K

Average Volume (3M)10.08K

Market Cap

₹987.25B

Enterprise Value₹1.04T

Total Cash (Recent Filing)₹31.05B

Total Debt (Recent Filing)₹83.69B

Price to Earnings (P/E)51.6

Beta0.54

Next Earnings

Aug 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.04%

Share Statistics

EPS (TTM)42.77

Shares Outstanding412,909,200

10 Day Avg. Volume5,924

30 Day Avg. Volume10,081

Financial Highlights & Ratios

PEG Ratio-7.55

Price to Book (P/B)5.08

Price to Sales (P/S)5.80

P/FCF Ratio43.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹2,636.75

Price Target Upside19.71% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

EPS Forecast (FY)58.05

Revenue Forecast (FY)₹159.79B

Bulls Say, Bears Say

Bulls Say

Diversified Business ModelMankind's mix of prescription branded formulations plus an OTC consumer-health portfolio creates diversified, recurring revenue streams. Physician-driven prescriptions provide stable trade sales while consumer brands generate repeat retail demand, reducing single-channel risk and supporting cash resilience over months.

Consistent Revenue GrowthSustained multi-year revenue growth indicates expanding product adoption and distribution scale. Consistent top-line expansion supports operational leverage, funding for marketing and R&D, and the ability to invest behind brands, which underpins durable competitive positioning over the medium term.

Solid Free Cash Flow GenerationConsistent positive free cash flow that covers a meaningful portion of earnings enhances financial flexibility. It supports reinvestment, dividend payments and debt reduction without relying on external financing, strengthening the firm's ability to execute strategic initiatives over the next several quarters.

Bears Say

Margin CompressionMaterial margin deterioration points to rising costs or adverse product mix that erode profitability even as sales grow. Lower margins reduce free cash conversion and limit room for reinvestment, making earnings more sensitive to cost inflation and competitive pricing over the medium term.

Weak Operating Cash ConversionOperating cash flow materially lagging reported earnings indicates weaker earnings quality, likely from working capital build or receivables. This reduces durable liquidity, constrains internal funding for growth, and raises the risk that earnings gains won't translate reliably into available cash.

Higher Leverage Vs HistoricalAlthough leverage recently improved, absolute debt remains higher than historical norms and ROE has declined, signaling lower returns on incremental capital. Elevated debt reduces balance-sheet flexibility and raises susceptibility to higher interest costs, limiting strategic optionality over coming quarters.

Mankind Pharma Ltd. News

Mankind Pharma Reshapes HR Leadership, Appoints Nilesh Kulkarni as Senior Management

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has shared an announcement. Mankind Pharma Limited has undertaken an internal organisational...

2d ago

Mankind Pharma Overhauls HR Leadership, Names Nilesh Kulkarni Group HR Head

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has issued an announcement. Mankind Pharma has restructured its human resources leadership,...

2d ago

Mankind Pharma Secures High CARE Ratings for ₹1,000 Crore Bank Facilities

An announcement from Mankind Pharma Ltd. ( ($IN:MANKIND) ) is now available. Mankind Pharma Limited has announced that...

2M ago

Mankind Pharma Publishes Q3 and Nine-Month FY26 Earnings Call Transcript

The latest update is out from Mankind Pharma Ltd. ( ($IN:MANKIND) ). Mankind Pharma Limited has released the...

4M ago

Mankind Pharma Challenges GST Order on Subsidiary Merger

Mankind Pharma Ltd. ( ($IN:MANKIND) ) just unveiled an announcement. Mankind Pharma Ltd. has announced that it received...

7M ago

Mankind Pharma Reports Strong Financial Performance for Q2 and H1 2025

The latest update is out from Mankind Pharma Ltd. ( ($IN:MANKIND) ). Mankind Pharma Ltd. announced its unaudited...

7M ago

Mankind Pharma Receives ESG Rating Score of 69

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has issued an update. Mankind Pharma Ltd. has received an ESG rating...

7M ago

Mankind Pharma Schedules Investor Conference Call for Q2 & H1 FY26

An update from Mankind Pharma Ltd. ( ($IN:MANKIND) ) is now available. Mankind Pharma Limited has announced an...

7M ago

Mankind Pharma’s MKP10241 Study: A Potential Game-Changer for Obesity and Diabetes Treatment?

Mankind Pharma Ltd. (($IN:MANKIND)) announced an update on their ongoing clinical study. Mankind Pharma Ltd. is conducting a...

8M ago

Mankind Pharma Reports No Share Dematerialisation Requests for Q3 2025

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has provided an announcement. Mankind Pharma Limited has announced that it has...

8M ago

MANKIND FAQ

What was Mankind Pharma Ltd.’s price range in the past 12 months?

Mankind Pharma Ltd. lowest stock price was ₹1909.90 and its highest was ₹2726.75 in the past 12 months.

What is Mankind Pharma Ltd.’s market cap?

Mankind Pharma Ltd.’s market cap is ₹987.25B.

When is Mankind Pharma Ltd.’s upcoming earnings report date?

Mankind Pharma Ltd.’s upcoming earnings report date is Aug 05, 2026 which is in 56 days.

How were Mankind Pharma Ltd.’s earnings last quarter?

Mankind Pharma Ltd. released its earnings results on May 19, 2026. The company reported ₹14 earnings per share for the quarter, beating the consensus estimate of ₹10.15 by ₹3.85.

Is Mankind Pharma Ltd. overvalued?

According to Wall Street analysts Mankind Pharma Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mankind Pharma Ltd. pay dividends?

Mankind Pharma Ltd. pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.04%. See more information on Mankind Pharma Ltd. dividends here

What is Mankind Pharma Ltd.’s EPS estimate?

Mankind Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mankind Pharma Ltd. have?

Mankind Pharma Ltd. has 412,909,200 shares outstanding.

What happened to Mankind Pharma Ltd.’s price movement after its last earnings report?

Mankind Pharma Ltd. reported an EPS of ₹14 in its last earnings report, beating expectations of ₹10.15. Following the earnings report the stock price went down -0.09%.

Which hedge fund is a major shareholder of Mankind Pharma Ltd.?

Currently, no hedge funds are holding shares in IN:MANKIND

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Mankind Pharma Ltd.

Mankind Pharma Limited specializes in the development, manufacturing, and marketing of a broad range of pharmaceutical medications and consumer health goods. Operating predominantly in India, the company also caters to international markets. Its pharmaceutical division focuses on both acute and chronic therapeutic areas, encompassing a wide spectrum of medical conditions such as infectious diseases, cardiovascular ailments, gastrointestinal disorders, diabetes, dermatology, pain management, neuro/CNS issues, nutritional support (vitamins/minerals), and respiratory problems. Complementing its pharmaceutical portfolio, the consumer healthcare segment offers diverse products, including condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. Key brands under its umbrella include Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar. Furthermore, the company's business activities are diversified, extending to the trading and export of pharmaceutical and healthcare products, as well as the manufacturing of various goods such as packaging materials, ayurvedic products, bulk drugs, and general consumer items. Mankind Pharma also holds interests in real estate, leasing, hospitality, and IT services. Established in 1986, Mankind Pharma Limited maintains its headquarters in New Delhi, India.

Mankind Pharma Ltd. (MANKIND) Earnings & Revenues

Historic Earnings Reports

MANKIND Stock 12 Month Forecast

Average Price Target

₹2,636.75

▲(19.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2000":"₹2,000","3001":"₹3,001","2250.25":"₹2,250.3","2500.5":"₹2,500.5","2750.75":"₹2,750.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹3.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2636.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.64K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2057,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.06K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2000,2250.25,2500.5,2750.75,3001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2320.35,2372.630769230769,2424.9115384615384,2477.1923076923076,2529.473076923077,2581.753846153846,2634.0346153846153,2686.3153846153846,2738.596153846154,2790.876923076923,2843.1576923076923,2895.4384615384615,2947.7192307692308,{"y":3000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2320.35,2344.6884615384615,2369.026923076923,2393.3653846153848,2417.703846153846,2442.0423076923075,2466.380769230769,2490.7192307692308,2515.0576923076924,2539.396153846154,2563.734615384615,2588.0730769230768,2612.4115384615384,{"y":2636.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2320.35,2300.0923076923077,2279.8346153846155,2259.576923076923,2239.3192307692307,2219.0615384615385,2198.8038461538463,2178.5461538461536,2158.2884615384614,2138.0307692307692,2117.773076923077,2097.5153846153844,2077.257692307692,{"y":2057,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2413.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2287.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2561.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2518.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2438.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2382.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2229.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2163.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2067.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2244.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2001.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2246.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2320.35,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >